Table 3.
Percent reduction in mAS scores and eBTD after piTBS
| Total muscles | Active (n = 76) | Sham (n = 44) | p-value |
|---|---|---|---|
| Percent Reduction in mASa | 0.27 ± 0.20 | 0.09 ± 0.15 | < 0.001** |
| Percent Reduction in eBTDa | 0.35 ± 0.34 | 0.11 ± 0.15 | < 0.001** |
| MCID* | 41 | 6 | < 0.001** |
| Upper limb | Active (n = 38) | Sham (n = 26) | p-value |
|---|---|---|---|
| Percent Reduction in mASa | 0.26 ± 0.20 | 0.11 ± 0.17 | 0.002** |
| Percent Reduction in eBTDa | 0.26 ± 0.27 | 0.13 ± 0.17 | 0.035** |
| Lower limb | Active (n = 38) | Sham (n = 18) | p-value |
|---|---|---|---|
| Percent Reduction in mASa | 0.27 ± 0.20 | 0.07 ± 0.13 | < 0.001** |
| Percent Reduction in eBTDa | 0.47 ± 0.39 | 0.08 ± 0.12 | < 0.001** |
n number of individual muscles, mAS modified Ashworth Scale, eBTD estimated Botulinum Toxin Dose
aPercent reduction after piTBS, (Mann Whitney test)
*MCID (minimal clinically important difference): ≥ 1 point reduction on Modified Ashworth scale (Pearson Chi-Square)
**Significant p-value < 0.05